Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-2736 in relapsed or refractory multiple myeloma
NCT05918250Phase 1Withdrawn
- Sponsor
- Moderna Inc
- Start
- Aug 2023
- Primary completion
- May 2026
- Modality
- mRNA Therapeutics
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of mRNA-2736 in multiple myeloma (MM), sponsored by Moderna Inc. Primary endpoint: Number of Participants Experiencing Adverse Events up to 1 year. Planned start Aug 2023; status: withdrawn.
02
Drugs
mRNA-2736
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05918250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05918250.